


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

| | |
|-------------------|---|
| USAN | PELIGLITAZAR |
| PRONUNCIATION | pel ee gli' ta zar |
| THERAPEUTIC CLAIM | Treatment of Type II diabetes mellitus, mixed dyslipidemia, atherosclerosis, and metabolic syndrome |

CHEMICAL NAMES

- 1) Glycine, *N*-[(4-methoxyphenoxy)carbonyl]-*N*-[(1*S*)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-
- 2) [[(4-methoxyphenoxy)carbonyl][(1*S*)-1-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]ethyl]amino]acetic acid

STRUCTURAL FORMULA



| | |
|----------------------------|---|
| MOLECULAR FORMULA | C ₃₀ H ₃₀ N ₂ O ₇ |
| MOLECULAR WEIGHT | 530.6 |
| TRADEMARK | Unknown as yet |
| MANUFACTURER | Bristol-Myers Squibb |
| CODE DESIGNATION | BMS-426707-01 |
| <u>CAS</u> REGISTRY NUMBER | 331744-64-0 |